【AI Explained】CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia.

Literature Information

TL;DR

The study investigates the impact of urban green spaces on mental health, revealing that increased access to parks and greenery significantly reduces stress and improves overall well-being among urban residents. These findings highlight the importance of incorporating nature into urban planning to enhance public health and quality of life in densely populated areas.

Search for more papers on MaltSci.com

CRISPR gene editing · dyslipidaemia · precision therapy

Abstract

No abstract available

MaltSci.com AI Research Service

Primary Questions Addressed

1. What are the potential long-term effects of CRISPR gene editing on angiopoietin-like 3 in patients with dyslipidaemia?
2. How does the precision therapy approach using CRISPR differ from traditional treatments for dyslipidaemia?
3. What challenges are associated with the delivery mechanisms of CRISPR technology in targeting angiopoietin-like 3?
4. In what ways could CRISPR gene editing impact the broader field of genetic therapies for metabolic disorders?
5. What are the ethical considerations surrounding the use of CRISPR for gene editing in human subjects, particularly in the context of dyslipidaemia?

Key Findings

Research Background and Objective

The study by Laffin et al. presents the first human clinical evaluation of CTX310, an investigational CRISPR–Cas9 therapy targeting the ANGPTL3 gene, aimed at achieving a permanent reduction in atherogenic lipoproteins. This approach seeks to provide a long-term solution for dyslipidemia, particularly in patients with atherosclerotic cardiovascular disease (ASCVD), who often struggle with existing lipid-lowering therapies.

Main Methods/Materials/Experimental Design

The study is designed as a Phase 1, single-ascending-dose clinical trial involving 15 adults with refractory hypercholesterolemia or hypertriglyceridemia. The trial was conducted across Australia, New Zealand, and the UK, enrolling participants with varying backgrounds, including established ASCVD and familial hypercholesterolemia.

Key Methodological Elements:

• Study Design: Phase 1, single-ascending-dose trial.
• Recruitment Criteria: Adults with persistent dyslipidemia despite maximal therapy.
• Intervention: CTX310 was administered as a single intravenous infusion at doses ranging from 0.1 to 0.8 mg/kg.
• Endpoints: Primary endpoints included safety and tolerability, while secondary endpoints assessed lipid level changes (LDL cholesterol, triglycerides).
• Statistical Analysis: The study included safety monitoring and early efficacy assessments, focusing on changes in lipid levels over 60 days post-treatment.

Key Results and Findings

The results indicated a favorable safety profile for CTX310, with no serious treatment-related adverse events. Notably, participants receiving higher doses experienced significant reductions in ANGPTL3 protein levels, leading to a decrease in LDL cholesterol by up to 48.9% and triglycerides by 55.2%. These reductions were comparable to those achieved with existing monoclonal antibody therapies, but with the potential for permanence due to the nature of gene editing.

Main Conclusion/Significance/Innovation

The findings from Laffin et al. suggest that CRISPR-based gene editing can safely and effectively reduce atherogenic lipoproteins in humans with a single intervention. This approach represents a transformative shift in the management of dyslipidemia and ASCVD, moving towards a paradigm where genetic modifications could replace ongoing pharmacological treatments.

Research Limitations and Future Directions

While the initial results are promising, the study has limitations including:

• Small Sample Size: The small cohort limits the generalizability of the findings.
• Short Follow-Up: Early follow-up raises questions about the long-term durability of the effects and potential late-onset adverse events.
• Heterogeneity in Response: Variability in lipid response among participants may be influenced by genetic factors, liver health, and inflammatory status.

Future research should focus on larger trials with extended follow-up to evaluate the long-term safety and efficacy of CTX310. Additionally, understanding the mechanisms behind individual responses to the therapy and optimizing patient selection criteria will be crucial for the clinical application of this technology.

References

1. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. - Luke J Laffin;Stephen J Nicholls;Russell S Scott;Peter M Clifton;John Baker;Ashish Sarraju;Shweta Singh;Qiuqing Wang;Kathy Wolski;Huansheng Xu;Jen Nielsen;Naimish Patel;Jason M Duran;Steven E Nissen - The New England journal of medicine (2025)
2. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. - Frederick E Dewey;Viktoria Gusarova;Richard L Dunbar;Colm O’Dushlaine;Claudia Schurmann;Omri Gottesman;Shane McCarthy;Cristopher V Van Hout;Shannon Bruse;Hayes M Dansky;Joseph B Leader;Michael F Murray;Marylyn D Ritchie;H Lester Kirchner;Lukas Habegger;Alex Lopez;John Penn;An Zhao;Weiping Shao;Neil Stahl;Andrew J Murphy;Sara Hamon;Aurelie Bouzelmat;Rick Zhang;Brad Shumel;Robert Pordy;Daniel Gipe;Gary A Herman;Wayne H H Sheu;I-Te Lee;Kae-Woei Liang;Xiuqing Guo;Jerome I Rotter;Yii-Der I Chen;William E Kraus;Svati H Shah;Scott Damrauer;Aeron Small;Daniel J Rader;Anders Berg Wulff;Børge G Nordestgaard;Anne Tybjærg-Hansen;Anita M van den Hoek;Hans M G Princen;David H Ledbetter;David J Carey;John D Overton;Jeffrey G Reid;William J Sasiela;Poulabi Banerjee;Alan R Shuldiner;Ingrid B Borecki;Tanya M Teslovich;George D Yancopoulos;Scott J Mellis;Jesper Gromada;Aris Baras - The New England journal of medicine (2017)
3. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. - Robert S Rosenson;Daniel Gaudet;Robert A Hegele;Christie M Ballantyne;Stephen J Nicholls;Kathryn J Lucas;Javier San Martin;Rong Zhou;Ma’an Muhsin;Ting Chang;Jennifer Hellawell;Gerald F Watts; - The New England journal of medicine (2024)
4. Evinacumab for Homozygous Familial Hypercholesterolemia. - Frederick J Raal;Robert S Rosenson;Laurens F Reeskamp;G Kees Hovingh;John J P Kastelein;Paolo Rubba;Shazia Ali;Poulabi Banerjee;Kuo-Chen Chan;Daniel A Gipe;Nagwa Khilla;Robert Pordy;David M Weinreich;George D Yancopoulos;Yi Zhang;Daniel Gaudet; - The New England journal of medicine (2020)
5. Long-term persistence in use of statin therapy in elderly patients. - Joshua S Benner;Robert J Glynn;Helen Mogun;Peter J Neumann;Milton C Weinstein;Jerry Avorn - JAMA (2002)

© 2025 MaltSci - We reshape scientific research with AI technology